Press release
Psoriasis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceu
Psoriasis Pipeline Analysis
DelveInsight reports that over 80 leading companies are actively engaged in the development of more than 80 therapeutic candidates aimed at treating Psoriasis.
Psoriasis Overview: Overview
Psoriasis is a long-lasting inflammatory skin disorder influenced by genetic predisposition, environmental triggers, and immune system dysfunction. It is not contagious and affects approximately 2% of the global population. The severity of the disease varies, with skin involvement categorized as mild (less than 2%), moderate (2-10%), or severe (over 10%). The most prevalent form is chronic plaque psoriasis, or psoriasis vulgaris. This condition is driven by the activation of immune cells such as dendritic cells, T-cells, macrophages, neutrophils, and keratinocytes, resulting in the formation of characteristic skin lesions. For mild to moderate cases, topical therapies remain the primary treatment option.
Request for a detailed insights report on Psoriasis pipeline insights [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Psoriasis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Psoriasis Therapeutics Market.
Key Takeaways from the Psoriasis Pipeline Report
*
DelveInsight's Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
*
In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for treating moderate to severe psoriasis in adults who are suitable candidates for systemic therapy or phototherapy. It is the first and only inhibitor of both IL-17A and IL-17F approved for treating adults with moderate to severe plaque psoriasis.
*
In October 2023, Arcutis Biotherapeutics announced that the FDA had approved a supplemental new drug application (sNDA) to expand the use of ZORYVE (roflumilast) cream 0.3% for topical treatment of plaque psoriasis, including areas with skin folds, for children aged 6 to 11 years.
*
In November 2020, Biohaven Pharmaceutical partnered with Weill Cornell Medicine to launch a clinical trial using a Biohaven CGRP-receptor antagonist for treating plaque psoriasis. CGRP, a neuropeptide, is thought to play a key role in the development of inflammatory skin conditions like psoriasis.
*
Key Psoriasis companies such as Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others are evaluating new drugs for Psoriasis to improve the treatment landscape.
*
Promising Psoriasis pipeline therapies in various stages of development include Topical roflumilast, GSK2982772, and others.
Psoriasis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Psoriasis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Psoriasis market.
Download our free sample page report on Psoriasis pipeline insights [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Psoriasis Emerging Drugs
*
Topical roflumilast: Arcutis Biotherapeutics
*
GSK2982772: GlaxoSmithKline
Psoriasis Companies
More than 80 prominent companies are actively developing treatments for psoriasis. Among these, Biocad has the most advanced drug candidates, which have reached the registration stage.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Psoriasis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Psoriasis Therapies and Key Companies: Psoriasis Clinical Trials and advancements [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Psoriasis Pipeline Therapeutic Assessment
- Psoriasis Assessment by Product Type
- Psoriasis By Stage
- Psoriasis Assessment by Route of Administration
- Psoriasis Assessment by Molecule Type
Download Psoriasis Sample report to know in detail about the Psoriasis treatment market @ Psoriasis Therapeutic Assessment [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Psoriasis Current Treatment Patterns
4. Psoriasis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Psoriasis Late-Stage Products (Phase-III)
7. Psoriasis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Psoriasis Discontinued Products
13. Psoriasis Product Profiles
14. Psoriasis Key Companies
15. Psoriasis Key Products
16. Dormant and Discontinued Products
17. Psoriasis Unmet Needs
18. Psoriasis Future Perspectives
19. Psoriasis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Psoriasis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriasis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-mylan-biocad-bristolmyers-squibb-celltrion-coherus-biosciences-janssen-pharmaceu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceu here
News-ID: 4127069 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
